Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity.

Our study suggests that stopping injectable disease-modifying treatments, in patients over 50 with disease inactivity, is not associated with an increased risk of relapse or EDSS progression, but there might be a higher risk of reaching EDSS 6. These results have to be confirmed by interventional studies.